Trump to announce all 50 states joining Medicaid drug pricing model

•1mo ago

Trump to announce all 50 states joining Medicaid drug pricing model

Tap title to read story

President Donald Trump announced that all fifty states, the District of Columbia, and Puerto Rico are participating in the Medicaid GENEROUS model, a program designed to implement most favored nation pricing for selected prescription drugs. The initiative aligns U.S. Medicaid net drug prices with lower rates paid in other affluent nations. The administration projects substantial savings over the coming decade, easing financial pressure on state-funded programs. Independent healthcare experts emphasize that actual savings remain unclear because specific manufacturer contract terms are not public. The announcement arrives as cost-of-living concerns dominate voter priorities ahead of the November midterm elections. While Medicaid beneficiaries pay only nominal prescription co-payments, lower net acquisition costs aim to relieve broader public healthcare spending. Critics note that existing federal rebate structures already secure substantial discounts, leaving the precise net fiscal impact subject to verification as state implementation proceeds across the country.

0:00 / 1:05

President Donald Trump announced that all fifty states, the District of Columbia, and Puerto Rico are participating in the Medicaid GENEROUS model, a program designed to implement most favored nation pricing for selected prescription drugs. The initiative aligns U.S. Medicaid net drug prices with lower rates paid in other affluent nations. The administration projects substantial savings over the coming decade, easing financial pressure on state-funded programs. Independent healthcare experts emphasize that actual savings remain unclear because specific manufacturer contract terms are not public. The announcement arrives as cost-of-living concerns dominate voter priorities ahead of the November midterm elections. While Medicaid beneficiaries pay only nominal prescription co-payments, lower net acquisition costs aim to relieve broader public healthcare spending. Critics note that existing federal rebate structures already secure substantial discounts, leaving the precise net fiscal impact subject to verification as state implementation proceeds across the country.

Published 2026-09-18 18:46:46 UTC · Published by JQJO

Published by JQJO Editorial Desk · AI assisted

More context

Timeline

On October 25 2024 President Trump signed executive order establishing pricing policy.
On May 15 2025 White House estimated billions in future healthcare savings.
On November 6 2025 CMS announced the voluntary GENEROUS Model initiative.
On January 15 2026 States submitted non-binding letters of intent to CMS.
On March 31 2026 Manufacturer application deadline closed for initial program phase.
On June 30 2026 Key terms negotiations concluded between CMS and drug manufacturers.
On July 1 2026 CMS published updated guidance documents regarding model rollout.
On August 31 2026 State participation agreement deadline concluded across all jurisdictions.
On September 18 2026 President Trump announced all fifty states joining program.
On November 3 2026 Voters head to polls during midterm elections nationwide.

Why it matters

Immediate US impact: Lowers state Medicaid prescription acquisition expenditures significantly. Possible long-term US impact: Potentially reduces federal healthcare spending across multiple decades. Most affected groups: State healthcare administrators and low-income Medicaid patients. Reader priority: Verify official state implementation details and independent financial analyses.

Coverage notes

Left: Emphasizes skepticism regarding projected savings and private pharmaceutical deals. Center: Reports official announcements alongside independent expert financial caution neutrally. Right: Highlights executive success in reducing costs for taxpayers.